Novo Holdings co-leads AnaCardio EUR 62.5 million Series B financing

PUBT · 1d ago
Novo Holdings co-leads AnaCardio EUR 62.5 million Series B financing
  • Novo Holdings co-led AnaCardio’s EUR 62.5 million Series B financing.
  • AnaCardio is a clinical-stage biotech developing AC01, an oral therapy for chronic advanced heart failure with reduced ejection fraction.
  • Proceeds fund Phase 2b development of AC01, targeting Phase 3 readiness by 2028.
  • Phase 1b/2a data showed a 22% rise in cardiac output and a 4.8-point ejection fraction gain at Day 28.
  • Phase 2b GOAL-HF2 aims to start enrolling in Q4 2026, studying two doses over 12 weeks in about 400 patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.